Establishment and application of hepatitis B virus persistent replication model in IFNAR^−/− mouse

Abstract

The type I interferon and IFNAR play an important role in hepatitis B virus (HBV) infection and anti-HBV therapy. However, its mechanism of action is still poorly understood. To gain more insights into the role of type I interferon and type I interferon receptor (IFNAR) in HBV infection, we established an HBV persistent replication IFNAR knockout (IFNAR^−/−) mouse model and preliminarily applied this model. At first, the progeny of IFNAR^−/− mouse was reproduced. Then hydrodynamic injection with pAAV/HBV1.2 plasmid was conducted to establish the persistent HBV replication IFNAR^−/− mouse model. At last, we applied this model to evaluate the effect of nucleoside analogues entecavir (ETV) on HBV replication. It was found that there was no difference in the serum HBsAg and HBeAg levels and HBcAg expression in the liver tissue between the ETV treated groups and normal saline (NS) treated group, but the serum HBV DNA levels were significantly suppressed 10, 25, 40 and 55 days after the ETV treatment [P=0.035, P=0.00, P=0.149 and P=0.084, IFNAR knockout (KO) control group vs. C57BL/6 ETV groups, respectively; P=0.081, P=0.001, P=0.243 and P=0.147, IFNAR KO control group vs. IFNAR KO ETV groups, respectively]. Interestingly, there was no difference in serum HBV DNA levels between the ETV treated IFNAR^−/− and C57BL/6 mice. This result suggests that HBV suppression during ETV treatments doesn’t depend on type I interferon and IFNAR. Collectively, persistent HBV replication IFNAR^−/− mouse model that we established is a useful and convenient tool to detect the function of the type I interferon and IFNAR in HBV infection and anti-HBV treatments.

Keywords

chronic hepatitis B / type I interferon receptor (IFNAR) / IFNAR^−/− mouse / type I Interferon / animal model

References

[1] LavanchyD. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol, 2005, 34(Suppl1): S1-3

[2] LaiCL, RatziuV, YuenMF, et al.. Viral hepatitis B. Lancet, 2003, 362(9401): 2089-2094

[3] Bhattacharya D, Thio CL. Review of hepatitis B therapeutics. Clin Infect Dis, 51(10):1201–1208

[4] DarnellJEJr, KerrIM, StarkGR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, 1994, 264(5164): 1415-1421

[5] HuangLR, WuHL, ChenPJ, et al.. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci U S A, 2006, 103(47): 17862-17867

[6] GaoZ, LiuFJ, LiuL, et al.. Application of hepatitis B virus replication mouse model. World J Gastroenterol, 2010, 16(16): 1979-1985

[7] ChenY, WuW, LiLJ, et al.. Comparison of the results for three automated immunoassay systems in determining serum HBV markers. Clin Chim Acta, 2006, 372(1–2): 129-133

[8] YehSH, TsaiCY, KaoJH, et al.. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol, 2004, 41(4): 659-666

[9] DetreS, Saclani JottiG, DowsettM. A “quickscore” method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol, 1995, 48(9): 876-878

[10] Wang BJ, Bao JJ, Wang JZ, et al. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J Gastroenterol, 17(28): 3322–3329

[11] LiuF, SongY, LiuD. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene therapy, 1999, 6(7): 1258-1266

[12] YangPL, AlthageA, ChungJ, et al.. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci U S A, 2002, 99(21): 13825-13830

[13] SuzukiT, TakeharaT, OhkawaK, et al.. Intravenous injection of naked plasmid DNA encoding hepatitis B virus (HBV) produces HBV and induces humoral immune response in mice. Biochem Biophys Res Commun, 2003, 300(3): 784-788

[14] PestkaS, KrauseCD, WalterMR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev, 2004, 202: 8-32

[15] AaronsonDS, HorvathCM. A road map for those who don’t know JAK-STAT. Science, 2002, 296(5573): 1653-1655

[16] DerSD, ZhouA, WilliamsBR, et al.. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A, 1998, 95(26): 15623-15628

[17] HansenBE, BusterEH, SteyerbergEW, et al.. Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment. J Med Virol, 2010, 82(7): 1135-1142

[18] Tian Y, Chen WL, Ou JH. Effects of interferon-alpha/beta on HBV replication determined by viral load. PLoS Pathog, 7(7):e1002159

[19] ZhouJ, HuangJD, PoonVK, et al.. Functional dissection of an IFN-alpha/beta receptor 1 promoter variant that confers higher risk to chronic hepatitis B virus infection. J Hepatol, 2009, 51(2): 322-332

[20] ZhouJ, LuL, YuenMF, et al.. Polymorphisms of type I interferon receptor 1 promoter and their effects on chronic hepatitis B virus infection. J Hepatol, 2007, 46(2): 198-205

[21] He XX, Chang Y, Jiang HJ, et al. Persistent effect of IFNAR-1 genetic polymorphism on the long-term pathogenesis of chronic HBV infection. Viral Immunol, 23(3): 251–257

[22] Meng F, Wang J, Ge J, et al. Alteration of interferon-alpha/beta receptors in chronic hepatitis B patients. J Clin Immunol, 31(3):521–532

[23] SongCH, YangB, ChenLM, et al.. IL-10 and IFN-γ serum changes during treatment of chronic HBV infection patients with ETV. Weichangbing Xue He Ganbing Xue Zazhi (Chinese), 2010, 19(12): 1114-1116

[24] YinL, QiaoWB, QuXJ, et al.. The study of interferon induced by nucleoside analogues. Shandong Yiyao (Chinese), 1996, 36(6): 5-6

[25] BhattacharyaD, ThioCL. Review of hepatitis B therapeutics. Clin Infect Dis, 2010, 51(10): 1201-1208

[26] LaiCL, ShouvalD, LokAS, et al.. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med, 2006, 354(10): 1011-1020

[27] ChangTT, GishRG, de ManR, et al.. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med, 2006, 354(10): 1001-1010

[28] WuJ, LuM, MengZ, et al.. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology, 2007, 46(6): 1769-1778

[29] WuJ, MengZ, JiangM, et al.. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology, 2009, 49(4): 1132-1140

[30] BroeringR, WuJ, MengZ, et al.. Toll-like receptor-stimulated non-parenchymal liver cells can regulate hepatitis C virus replication. J Hepatol, 2008, 48(6): 914-922